Rentschler ATMP was launched by Rentschler Biopharma in 2021 to provide high-quality viral vectors for advanced therapy medicinal products (ATMP).
Rentschler Biopharma is a leading global CDMO, focused exclusively on client projects. Thanks to our 50 years of proven scientific expertise in biotechnology, we count ourselves among the leaders in the industry. From our headquarters in Laupheim, Germany, and our site in Milford, USA, we offer end-to-end solutions including biopharmaceutical process development and cGMP manufacturing.
Our Center of Excellence for cell and gene therapy is located in the UK largest cell and gene therapy cluster Stevenage. At Rentschler ATMP, we are dedicated to advancing cell and gene therapy products from development to cGMP manufacturing for our clients and their patients.